TD Asset Management
APLS

TD Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

TD Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,692
Closed -$1.23M – 1218
2024
Q4 		$1.23M Sell
38,692
-199,520
-84% -$6M ﹤0.01% 1088
2024
Q3 		$7.02M Sell
238,212
-73,620
-24% -$2.73M 0.01% 713
2024
Q2 		$12M Sell
311,832
-147,570
-32% -$6.68M 0.01% 592
2024
Q1 		$27M Sell
459,402
-23,920
-5% -$1.52M 0.03% 418
2023
Q4 		$28.9M Buy
483,322
+112,465
+30% +$5.71M 0.03% 388
2023
Q3 		$14.1M Sell
370,857
-107,869
-23% -$4.74M 0.02% 508
2023
Q2 		$43.6M Buy
478,726
+100,758
+27% +$8.69M 0.05% 293
2023
Q1 		$24.9M Buy
377,968
+106,348
+39% +$6.14M 0.03% 402
2022
Q4 		$14M Sell
271,620
-7,096
-3% -$376K 0.02% 518
2022
Q3 		$18.2M Buy
278,716
+4
+0% +$237 0.02% 431
2022
Q2 		$12.6M Buy
278,712
+31,026
+13% +$1.41M 0.01% 546
2022
Q1 		$12.6M Buy
247,686
+86,641
+54% +$3.82M 0.01% 597
2021
Q4 		$7.61M Buy
161,045
+41,381
+35% +$1.63M 0.01% 748
2021
Q3 		$3.94M Sell
119,664
-19,738
-14% -$1.11M ﹤0.01% 886
2021
Q2 		$8.92M Buy
139,402
+36,779
+36% +$1.9M 0.01% 681
2021
Q1 		$4.4M Buy
102,623
+26,180
+34% +$1.24M ﹤0.01% 864
2020
Q4 		$4.37M Buy
76,443
+9,700
+15% +$410K 0.01% 827
2020
Q3 		$2.01M Hold
66,743
– – ﹤0.01% 905
2020
Q2 		$2.18M Buy
66,743
+35,500
+114% +$1.14M ﹤0.01% 858
2020
Q1 		$837K Buy
31,243
+8,478
+37% +$301K ﹤0.01% 1045
2019
Q4 		$697K Hold
22,765
– – ﹤0.01% 1184
2019
Q3 		$548K Buy
22,765
+5,824
+34% +$160K ﹤0.01% 1159
2019
Q2 		$429K Hold
16,941
– – ﹤0.01% 1207
2019
Q1 		$330K Sell
16,941
-2,900
-15% -$45.6K ﹤0.01% 1247
2018
Q4 		$262K Buy
19,841
+400
+2% +$6.14K ﹤0.01% 1323
2018
Q3 		$346K Hold
19,441
– – ﹤0.01% 1353
2018
Q2 		$428K Buy
+19,441
New +$447K ﹤0.01% 1292

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TD Asset Management's APLS Position: Q1 2025 in Review

TD Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 38,692 shares — an estimated $1.23M sold.

TD Asset Management first reported a position in APLS in Q2 2018 and held it in 27 quarters. The position peaked at $43.6M in Q2 2023. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

  • TD Asset Management reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • TD Asset Management sold 38,692 Apellis Pharmaceuticals shares in Q1 2025, an estimated $1.23M.
  • TD Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 27 quarters.
  • TD Asset Management's Apellis Pharmaceuticals position peaked at $43.6M in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.